This winter, life science conference leader, Q1 Productions, will host its Medical Communications & the Dissemination of Scientific Information Conference in pharmaceutical hub, Cambridge, Massachusetts*. Exploring various areas from the special role medical writers play in keeping pharmaceutical companies compliant, to the move from medical writing toward information engagement, this conference will bring together leading pharmaceutical executives to shed light on the issues most important to medical communicators.
With regulatory scrutiny on the rise, medical communications departments are having to adjust to increased transparency concerns and adherence to new and changing legal guidelines. Writers and planners continually look to craft their content in a compelling and effective manner, while leveraging the goals of their marketing departments and remaining compliant. Maximizing this synergy between scientific and corporate information creates most beneficial platforms and strategies for reaching stakeholders.
As the industry has begun to see, reaching stakeholders continues to move into electronic formats, with social networking sites becoming one of the most powerful tools for medical communicators and patients alike. Q1's Medical Communications & the Dissemination of Scientific Information Conference will look at the industry's developing trends through case study-driven presentations, panel discussions and more, ultimately providing pharmaceutical executives with a clearer strategy for maximizing scientific information dissemination. For full details and/or registration, visit: http://www.Q1Productions.com/medicalcommunications
Presenting organizations include: Amgen, Arnall Golden Gregory LLP, Biogen Idec, British Medical Journal, Cephalon, Elsevier, Foley & Lardner LLP, Foley Hoag LLP, GlaxoSmithKline Research & Development, Genzyme, Human Genome Sciences, Inc., International Journal of Clinical Practice, Johns Hopkins Medicine, Millenium: The Takeda Oncology Company, Novartis, Novo Nordisk, Pfizer, Shionogi Inc., Shire Pharmaceuticals and Vertex Pharmaceuticals
source: Medical News Today
No comments:
Post a Comment